Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery:: Formulation, optimisation and in vitro characterisation

被引:465
作者
Motwani, Sanjay K. [1 ]
Chopra, Shruti [1 ]
Talegaonkar, Sushma [1 ]
Kohl, Kanchan [1 ]
Ahmad, Farhan J. [1 ]
Khar, Roop K. [1 ]
机构
[1] Fac Pharm, Dept Pharmaceut, New Delhi 110062, India
关键词
optimisation; response surface methodology; Box-Behnken design; formulation; mucoadhesion; nanoparticles;
D O I
10.1016/j.ejpb.2007.09.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Management of extraocular disease is mainly limited by the inability to provide long-term extraocular drug delivery without avoiding the systemic drug exposure and/or affecting the intraocular structures and poor availability of drugs, which may be overcome by prolonging the contact time with the ocular surface, for instance with bioadhesive polymers. In the present study, mucoadhesive chitosan (CS)-sodium alginate (ALG) nanoparticles were investigated as a new vehicle for the prolonged topical ophthalmic delivery of antibiotic, gatifloxacin. A modified coacervation or ionotropic gelation method was used to produce gatifloxacin-loaded submicroscopic nanoreservoir systems. It was optimised using design of experiments by employing a 3-factor, 3-level Box-Behnken statistical design. Independent variables studied were the amount of the bioadhesive polymers: CS, ALG and the amount of drug in the formulation. The dependent variables were the particle size, zetapotential, encapsulation efficiency and burst release. Response surface plots were drawn, statistical validity of the polynomials was established and optimised formulations were selected by feasibility and grid search. Nanoparticles were characterised by FT-IR, DSC, TEM and atomic force microscopy. Drug content, encapsulation efficiency and particle properties such as size, size distribution (polydispersity index) and zetapotential were determined. The designed nanoparticles have average particle size from 205 to 572 nm (polydispersity from 0.325 to 0.489) and zetapotential from 17.6 to 47.8 mV. Nanoparticles revealed a fast release during the first hour followed by a more gradual drug release during a 24-h period following a non-Fickian diffusion process. Box-Behnken experimental design thus facilitated the optimisation of mucoadhesive nanoparticulate carrier systems for prolonged ocular delivery of the drug. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:513 / 525
页数:13
相关论文
共 64 条
[1]   Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].
Agnihotri, SA ;
Mallikarjuna, NN ;
Aminabhavi, TM .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28
[2]   Nanomedicines for overcoming biological barriers [J].
Alonso, MJ .
BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) :168-172
[3]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[4]   Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers [J].
Aspden, TJ ;
Mason, JDT ;
Jones, NS ;
Lowe, J ;
Skaugrud, O ;
Illum, L .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (04) :509-513
[5]   Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for antiinflammatory drugs [J].
Berthold, A ;
Cremer, K ;
Kreuter, J .
JOURNAL OF CONTROLLED RELEASE, 1996, 39 (01) :17-25
[6]   MICROENCAPSULATION OF DRUGS WITH AQUEOUS COLLOIDAL POLYMER DISPERSIONS [J].
BODMEIER, R ;
WANG, JJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (02) :191-194
[7]  
Box GEP., 1960, TECHNOMETRICS, V2, P455, DOI [10.2307/1266454, DOI 10.1080/00401706.1960.10489912, 10.1080/00401706.1960.10489912]
[8]   Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers [J].
Calvo, P ;
VilaJato, JL ;
Alonso, MJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (01) :41-50
[9]  
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[10]  
2-4